In:
Journal of Immunotherapy and Precision Oncology, Innovative Healthcare Institute, Vol. 2, No. 4 ( 2019-11-01), p. 152-155
Abstract:
Mesenchymal–epithelial transition factor (MET) amplification has been suggested either as a de novo or acquired mechanism of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy. However, even if MET amplification has been widely described in the preclinical setting, only a few clinical data have confirmed the role of MET in the resistance to anti-EGFR treatment. A 60-year-old man presenting cholangiocarcinoma with EGFR amplification had a tumor response to anti-EGFR therapy. A new on-purpose tumor biopsy performed during tumor progression confirmed the known EGFR amplification as well as a new MET amplification. This clinical observation highlights the role of MET amplification as a mechanism of resistance to EGFR inhibitors.
Type of Medium:
Online Resource
ISSN:
2590-017X
,
2666-2345
DOI:
10.4103/JIPO.JIPO_7_19
Language:
English
Publisher:
Innovative Healthcare Institute
Publication Date:
2019
detail.hit.zdb_id:
3032799-4
Permalink